n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans

William Harris, Gro Siri Rambjør, Sheryl L. Windsor, Dennis Diederich

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Fish oils rich in n=3 fatty acids have been shown to augment endothelium-dependent vasodilation in human peripheral and coronary arteries. This suggests that n=3 fatty acids may enhance arterial nitric oxide production. To explore this hypothesis we measured total urinary nitrate output in healthy volunteers supplemented with a fish oil concentrate (FOC; n = 15) or purified eicosapentaenoic acid (EPA; n = 14) in a placebo- controlled, parallel-group study. The FOC contained 41% EPA and 23% docosahexaenoic acid (DHA) ethyl esters, whereas EPA was 91% pure; the placebo contained olive oil ethyl esters. Doses were 5 g placebo, 5 g FOC, and 3 g EPA to keep the total n=3 fatty acid content equal in the latter two groups. The placebo period was 2 wk long and was followed by a 3-wk n=3 fatty acid phase. At the end of each period, 24-h urine collections and fasting blood samples were obtained. Serum and urinary nitrate concentrations were measured in a blinded fashion. The FOC produced a 43% increase in daily, creatinine-adjusted, nitrate excretion rates (P <0.029). Because serum nitrate concentrations were not different, these findings suggest that FOC supplementation may stimulate systemic nitric oxide synthesis. The lack of effect with EPA supplementation suggests that this component of the FOC is not likely to be an active component. If confirmed, these observations suggest another mechanism whereby n=3 fatty acids may be antiatherogenic.

Original languageEnglish (US)
Pages (from-to)459-464
Number of pages6
JournalAmerican Journal of Clinical Nutrition
Volume65
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
omega-3 fatty acids
nitric oxide
Nitric Oxide
excretion
Nitrates
placebos
metabolites
Placebos
nitrates
Fish Oils
blood serum
esters
fatty fish
Urine Specimen Collection
Eicosapentaenoic Acid
vasodilation
coronary vessels
eicosapentaenoic acid
endothelium

Keywords

  • docosahexaenoic acid
  • eicosapentaenoic acid
  • Fish oil
  • nitric oxide
  • vascular endothelium

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Harris, W., Rambjør, G. S., Windsor, S. L., & Diederich, D. (1997). n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. American Journal of Clinical Nutrition, 65(2), 459-464.

n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. / Harris, William; Rambjør, Gro Siri; Windsor, Sheryl L.; Diederich, Dennis.

In: American Journal of Clinical Nutrition, Vol. 65, No. 2, 1997, p. 459-464.

Research output: Contribution to journalArticle

Harris, W, Rambjør, GS, Windsor, SL & Diederich, D 1997, 'n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans', American Journal of Clinical Nutrition, vol. 65, no. 2, pp. 459-464.
Harris, William ; Rambjør, Gro Siri ; Windsor, Sheryl L. ; Diederich, Dennis. / n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. In: American Journal of Clinical Nutrition. 1997 ; Vol. 65, No. 2. pp. 459-464.
@article{fcbac7e26f864e34a5be733a2c25edc6,
title = "n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans",
abstract = "Fish oils rich in n=3 fatty acids have been shown to augment endothelium-dependent vasodilation in human peripheral and coronary arteries. This suggests that n=3 fatty acids may enhance arterial nitric oxide production. To explore this hypothesis we measured total urinary nitrate output in healthy volunteers supplemented with a fish oil concentrate (FOC; n = 15) or purified eicosapentaenoic acid (EPA; n = 14) in a placebo- controlled, parallel-group study. The FOC contained 41{\%} EPA and 23{\%} docosahexaenoic acid (DHA) ethyl esters, whereas EPA was 91{\%} pure; the placebo contained olive oil ethyl esters. Doses were 5 g placebo, 5 g FOC, and 3 g EPA to keep the total n=3 fatty acid content equal in the latter two groups. The placebo period was 2 wk long and was followed by a 3-wk n=3 fatty acid phase. At the end of each period, 24-h urine collections and fasting blood samples were obtained. Serum and urinary nitrate concentrations were measured in a blinded fashion. The FOC produced a 43{\%} increase in daily, creatinine-adjusted, nitrate excretion rates (P <0.029). Because serum nitrate concentrations were not different, these findings suggest that FOC supplementation may stimulate systemic nitric oxide synthesis. The lack of effect with EPA supplementation suggests that this component of the FOC is not likely to be an active component. If confirmed, these observations suggest another mechanism whereby n=3 fatty acids may be antiatherogenic.",
keywords = "docosahexaenoic acid, eicosapentaenoic acid, Fish oil, nitric oxide, vascular endothelium",
author = "William Harris and Rambj{\o}r, {Gro Siri} and Windsor, {Sheryl L.} and Dennis Diederich",
year = "1997",
language = "English (US)",
volume = "65",
pages = "459--464",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "2",

}

TY - JOUR

T1 - n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans

AU - Harris, William

AU - Rambjør, Gro Siri

AU - Windsor, Sheryl L.

AU - Diederich, Dennis

PY - 1997

Y1 - 1997

N2 - Fish oils rich in n=3 fatty acids have been shown to augment endothelium-dependent vasodilation in human peripheral and coronary arteries. This suggests that n=3 fatty acids may enhance arterial nitric oxide production. To explore this hypothesis we measured total urinary nitrate output in healthy volunteers supplemented with a fish oil concentrate (FOC; n = 15) or purified eicosapentaenoic acid (EPA; n = 14) in a placebo- controlled, parallel-group study. The FOC contained 41% EPA and 23% docosahexaenoic acid (DHA) ethyl esters, whereas EPA was 91% pure; the placebo contained olive oil ethyl esters. Doses were 5 g placebo, 5 g FOC, and 3 g EPA to keep the total n=3 fatty acid content equal in the latter two groups. The placebo period was 2 wk long and was followed by a 3-wk n=3 fatty acid phase. At the end of each period, 24-h urine collections and fasting blood samples were obtained. Serum and urinary nitrate concentrations were measured in a blinded fashion. The FOC produced a 43% increase in daily, creatinine-adjusted, nitrate excretion rates (P <0.029). Because serum nitrate concentrations were not different, these findings suggest that FOC supplementation may stimulate systemic nitric oxide synthesis. The lack of effect with EPA supplementation suggests that this component of the FOC is not likely to be an active component. If confirmed, these observations suggest another mechanism whereby n=3 fatty acids may be antiatherogenic.

AB - Fish oils rich in n=3 fatty acids have been shown to augment endothelium-dependent vasodilation in human peripheral and coronary arteries. This suggests that n=3 fatty acids may enhance arterial nitric oxide production. To explore this hypothesis we measured total urinary nitrate output in healthy volunteers supplemented with a fish oil concentrate (FOC; n = 15) or purified eicosapentaenoic acid (EPA; n = 14) in a placebo- controlled, parallel-group study. The FOC contained 41% EPA and 23% docosahexaenoic acid (DHA) ethyl esters, whereas EPA was 91% pure; the placebo contained olive oil ethyl esters. Doses were 5 g placebo, 5 g FOC, and 3 g EPA to keep the total n=3 fatty acid content equal in the latter two groups. The placebo period was 2 wk long and was followed by a 3-wk n=3 fatty acid phase. At the end of each period, 24-h urine collections and fasting blood samples were obtained. Serum and urinary nitrate concentrations were measured in a blinded fashion. The FOC produced a 43% increase in daily, creatinine-adjusted, nitrate excretion rates (P <0.029). Because serum nitrate concentrations were not different, these findings suggest that FOC supplementation may stimulate systemic nitric oxide synthesis. The lack of effect with EPA supplementation suggests that this component of the FOC is not likely to be an active component. If confirmed, these observations suggest another mechanism whereby n=3 fatty acids may be antiatherogenic.

KW - docosahexaenoic acid

KW - eicosapentaenoic acid

KW - Fish oil

KW - nitric oxide

KW - vascular endothelium

UR - http://www.scopus.com/inward/record.url?scp=0030897717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030897717&partnerID=8YFLogxK

M3 - Article

C2 - 9022531

AN - SCOPUS:0030897717

VL - 65

SP - 459

EP - 464

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 2

ER -